Collectively, our preclinical study suggests that targeting CDK4/6 could serve as a promising therapeutic approach for treating CRC and other cancers characterized by overexpression of wild‐type DUB3 and YAP1 (Figure 6D). Here, USP17L2 is linked to colorectal carcinoma.